Performance evaluation of the DAAN HCV assay for quantification of hepatitis C virus RNA and its comparison with COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0

Yuting He1 | Yichong Wang1 | Xuefang Chen2 | Hao Huang1 | Jiankai Deng1 | Peisong Chen1 | Huang Bin1

Abstract

Background: The Daan HCV RNA quantitative assay was a recently developed kit with high sensitivity for the detection of HCV RNA. We aimed to evaluate the analytical performance of the Daan HCV RNA quantitative assay and compare it with the COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0.

Method: WHO HCV RNA standard, NIBSC 06/102 standard, and CLSI EP documents were used to evaluate the precision, accuracy, linearity, anti-interference ability, and cross-reactivity of the Daan HCV RNA quantitative assay. Overall 198 clinical serum specimens were used to make comparison between the Daan HCV RNA quantitative assay and the Roche Cobas test.

Results: The within-run precision ($S_{\text{within}}$), and total precision ($S_{\text{total}}$) for 6.11 log IU/mL, 4.22 log IU/mL, and 2.32 log IU/mL HCV RNA were 0.13 and 0.15, 0.07 and 0.09, and 0.11 and 0.10, respectively. The linear range was $10^{-4}$ IU/mL, and the limit of detection was 15 IU/mL. It did not display any interference with commonly encountered conditions and cross-reactivity with some common virus. A good agreement was observed between the Daan HCV RNA quantitative assay and the Roche Cobas test.

Conclusion: The Daan HCV RNA quantitative assay has shown satisfactory performances and excellent agreement with COBAS HCV Quantitative Test on clinical specimens with lower cost, which provides an alternative choice for the diagnosis and monitoring of HCV infection in developing countries.

Keywords

DAAN HCV assay, HCV RNA quantitative assay, hepatitis C virus RNA, methodology comparison, performance evaluation, Roche Cobas test
Hepatitis C virus (HCV) infection remains a significant public health in developing countries, leading to liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. According to the HCV prevalence statistics by the World Health Organization, there were 69.6 million HCV-infected individuals in 2016 globally. HCV infection exhibits clinically as acute and chronic hepatitis and is characterized by diffuse liver damage. Generally, the infection progresses to a chronic state in 80% of patients, many of whom remain asymptomatic for a long time. It is recommended to measure HCV RNA levels repeatedly during antiviral therapy to determine treatment efficacy and adherence.

Currently, HCV RNA levels can be quantified by direct measurement of its level in plasma or serum using real-time polymerase chain reaction (PCR) combined with reverse transcription (RT) or signal amplification methods such as branch DNA (b-DNA) and reverse transcription loop-mediated isothermal amplification (RT-LAMP) assays. At present, HCV RNA quantitation has many proprietary systems commercialized by elite companies, such as Roche, Siemens, and Abbott. Meanwhile, HCV PCR quantitative assays are also commercialized by diverse companies such as Hologic, Qiagen, Cepheid, Sacace, Fast-tracks Diagnostics, and Biocentric. The diagnostic kit for quantification of hepatitis C virus RNA (Daan) is a recently developed and certified kit by China Food and Drug Administration (CFDA). The assay applies the real-time PCR technology with PCR-fluorescence probing method. The COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0 (Roche) is a widely used, FDA-approved HCV assay with excellent performance which is comparable to that of other assays. In this present study, we evaluated the analytical performance of the recently developed and certified diagnostic kit for quantification of hepatitis C virus RNA (Daan), including precision, accuracy, linearity, limit of detection (LOD), interference, and cross-reactivity study. Then, the HCV RNA quantitative results of the clinical specimens gained using this assay were compared with those gained with the Roche Cobas test.

2 | MATERIALS AND METHODS

2.1 | Test devices and instruments

The diagnostic kit for quantification of HCV RNA (Daan) utilizes the real-time PCR technology with PCR-fluorescence probing targeting the highly conserved region of HCV and go through a one-step RT-PCR to detect the HCV RNA in the plasma or serum. Briefly, HCV RNA was extracted with internal control from 200 μL of serum or plasma and detected by PCR-fluorescence probing. The internal control is spiked synthetic sequences. It is included in this kit to ensure the sample is extracted properly and there is no carryover of PCR-inhibitors, reducing the occurrence of false-negative results. The reaction conditions were in line with the manufacturer’s instruction (50°C for 15 minutes, 1 cycle; 95°C for 15 minutes, 1 cycle; 94°C for 15 seconds, 55°C for 45 seconds, 45 cycles; 40°C for 2 seconds, 1 cycle). The extraction of the HCV RNA was performed using automatic nucleic acids extraction apparatus Smart 32 (Daan), and the detection was carried out using the Applied Biosystems 7500 Real-time fluorescent quantitative PCR instrument (Thermo).

2.2 | Precision

To evaluate the precision, the World Health Organization (WHO) HCV RNA standard was used which contained 6.11 log IU/mL (1.3 × 10^4 IU/mL), 4.22 log IU/mL (1.66 × 10^3 IU/mL), and 2.32 log IU/mL (2.10 × 10^2 IU/mL), respectively. The American Clinical and Laboratory Standards Institute (CLSI) documents were used as guideline for the design of the experiments. According to CLSI document EP15-A2, the three HCV RNA concentrations were tested in five replicates a day, respectively, and the detection lasted for 5 days. Within-run precision (σ_{within}), variance term (B), and total precision (σ_{total}) were calculated and compared with the within-run precision claimed by the manufacturer (σ_{within}) and total precision claimed by the manufacturer (σ_{total}). The computational formula for those parameters is shown in Supplementary Material.

2.3 | Accuracy

To evaluate the accuracy, the 6 log IU/mL HCV RNA reference (National Institute for Biological Standards and Control (NIBSC) 06/102 standard) was used and diluted with HCV-negative serum to generate five dilutions with nominal HCV RNA concentrations of 10^5, 10^4, 10^3, 10^2, 50 IU/mL and each dilution was tested in 3 replicates.

2.4 | Linearity

The high constant concentration sample (2.0 × 10^8 IU/mL) was diluted with HCV-negative serum to generate nine dilutions with nominal HCV RNA concentrations of 10^5, 10^4, 10^3, 10^2, 10, 50, 20 IU/mL, and each dilution was tested in 3 replicates.

2.5 | Limit of detection (LOD)

3 log IU/mL HCV RNA reference (NIBSC 06/102 standard) was diluted with HCV-negative serum to generate four dilutions with nominal HCV RNA concentrations of 50, 20, 15, 10 IU/mL, and each dilution was tested in 25 replicates. The LOD was defined as the lowest HCV RNA level detected 95% of the times.

2.6 | Interference and cross-reactivity study

The interference experiment was carried out using the HCV RNA interfering substance kit (Daan), which took HCV RNA-positive serum
(WHO international standard, NIBSC code: 06/102) and five kinds of interfering substances as raw materials to generate serums with 30 mg/dL bilirubin, 3.2 g/dL triglyceride, 30 g/dL hemoglobin, 6 g/dL albumin, or 18 g/L total immunoglobulin G, containing $2.21 \times 10^5$ IU/mL HCV RNA or $2.77 \times 10^3$ IU/mL HCV RNA. The two kinds of HCV RNA concentration serum with different interfering substances went through the HCV RNA quantitative assay to evaluate the effect of different interfering substances on the high concentration or low concentration HCV RNA-positive serum. Moreover, the HCV RNA-negative serums with 30 mg/dL bilirubin, 3.2 g/dL triglyceride, 30 g/dL hemoglobin, 6 g/dL albumin, or 18 g/L total immunoglobulin G were also tested. Five specimens positive for hepatitis B virus (HBV), five specimens positive for cytomegalovirus (CMV), and five specimens positive for Epstein-Barr virus (EBV) and dengue virus (DV) were tested for the cross-reactivity study. The specimens used for cross-reactivity study were negative for HCV RNA.

### 2.7 Comparison between Daan HCV RNA quantitative assay and COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0

One hundred and ninety eight specimens quantitated by COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0 in the First Affiliated Hospital, Sun Yat-sen University from April to October 2019 were collected to evaluate the clinical performance of Daan HCV RNA quantitative assay. The serum was stored at $-80^\circ$C until detected by Daan HCV RNA quantitative assay.

### 2.8 Statistical analysis

HCV RNA quantities were log10 transformed before analysis. The variability among Daan HCV RNA quantitative assays was presented by the standard deviation (SD) and the percent coefficient of variation (CV) for the log10 transformed values. Linearity was analyzed by linear regression using the data from 3 replicates of serial dilutions. Deming regression analysis, Bland-Altman analysis and Spearman’s correlation coefficient were used to compare agreement of quantitative results for the positive specimens obtained by the two methods. Microsoft Excel, GraphPad Prism 6.0 (GraphPad Software), and MedCalc (MedCalc Software) were used to perform statistical analyses.

### 3 RESULTS

#### 3.1 Precision and Accuracy

The $S_{\text{within}}$, $B$, and $S_{\text{total}}$ of the three concentrations of HCV RNA were calculated and shown in Table 1. The manufacturer’s claim with-run coefficient of variation ($CV_{\text{within}}$) and total coefficient of variation ($CV_{\text{total}}$) were both 5%. Thus, the $s_{\text{within}}$ and $s_{\text{total}}$ for 6.11 log IU/mL, 4.22 log IU/mL, and 2.32 log IU/mL HCV RNA were 0.31, 0.21, and 0.12, respectively. Compared with the $s_{\text{within}}$ and $S_{\text{total}}$, $S_{\text{within}}$ of 6.11 log IU/mL and 4.22 log IU/mL were much less than the $s_{\text{within}}$ and $s_{\text{total}}$, indicating excellent precision of high and medium concentrations of HCV RNA. However, the $S_{\text{within}}$ and $S_{\text{total}}$ of 2.32 log IU/mL were close to the $s_{\text{within}}$ and $s_{\text{total}}$, suggesting the precision of low concentration HCV RNA was inferior to that of high and medium concentrations and variation was larger among assays with low concentration of HCV RNA. The SDs and CVs for different concentrations of HCV RNA were shown in Table 2. The CVs of $10^5$, $10^4$, $10^3$, and $10^2$ IU/mL were all below 5%, while the CV of 50 IU/mL was 11%. The CVs of each concentration indicated excellent accuracy. Moreover, the variation intended to become larger with the concentration decreasing.

#### 3.2 Linearity and limit of detection (LOD)

As shown in Figure 1, the Daan HCV RNA quantitative assay exhibited a linear response from 1.3 log IU/mL to 8 log IU/mL. The equation for the linear regression line was $y = 1.034 \times x - 0.1351$, and the slope of 1.034 had a 95% confidence interval of 0.9889 to 1.080, including 1.00. The $R^2$ values for the linear goodness of fit were 0.9976. The HCV RNA detection rates for nominal HCV RNA concentrations of 50, 20, 15, and 10 IU/mL were 100%, 100%, 100%, and 84%, respectively. The specific HCV RNA quantitative results were shown in Table S1. The LOD was defined as the lowest HCV RNA level detected 95% of the times. As a result, the LOD was 15 IU/mL.

#### 3.3 Interference and cross-reactivity study

The results of the Daan HCV RNA quantitative assay for HCV RNA-positive serum with different interfering substances were shown in Table 3. All the results were in the expected range, indicating bilirubin (up to 30 mg/dL), triglyceride (up to 3.2 g/dL), hemoglobin (up to 30 g/dL), albumin (up to 6 g/dL), or total immunoglobulin G (up to 18 g/L) did not influence the accurate detection of high concentration or low concentration HCV RNA-positive serum. The negative serums with different interfering substances above were all tested negative. The Daan HCV RNA quantitative assay had not detected HCV RNA in the specimens positive for HBV, CMV, EBV, or DV. Thus, Daan HCV RNA quantitative assay showed no cross-reactivity with HBV, CMV, EBV, and DV infections.

#### 3.4 Agreement between Daan HCV RNA quantitative assay and COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test

Among 81 specimens tested positive by COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, all were tested positive by the Daan HCV RNA quantitative assay. Of the 117 specimens tested negative...
by the Roche Cobas test, 115 specimens were tested negative by the Daan HCV RNA quantitative assay. The HCV viral load of the inconsistent samples was both below the LOD of Roche Cobas test and the Daan HCV RNA quantitative assay (both 15 IU/mL). Comparable performance of quantitative detection was illustrated by Deming regression analysis and Bland-Altman analysis. A good correlation was observed between the two assays (Figure 2A). The median (IQR) HCV RNA concentration for Daan HCV RNA quantitative assay and the Roche Cobas test were 5.63 (1.82-7.31) log IU/mL and 5.7 (1.9-7.41) log IU/mL, respectively. Good agreement was observed by Bland-Altman analysis between the two assays (Figure 2B), showing 77 quantitative results were within 95% limit of agreement among the 81 HCV RNA-positive specimens. The mean difference (bias ± SD) between the Daan HCV RNA quantitative assay and the Roche Cobas test was −0.07 ± 0.37 log IU/mL.

### DISCUSSION

It is necessary for an HCV RNA quantitative assay to provide reliable results and wide range of quantification because the chronically infected patients had wide ranges of HCV viral load. Moreover, broad-range quantification was needed to monitor the response of the HCV-infected patients to undetectable therapy levels of virus load. The $S_{\text{within}}$ and $S_{\text{total}}$ of the Daan HCV RNA quantitative assay for each verified concentration had reached the standard claimed by the manufacturer, demonstrating excellent precision of the quantitative assay. The greatest variability was observed with the low (2.32 log IU/mL) HCV RNA concentration which may be caused by RNA degradation. According to the results of linearity, the Daan HCV RNA quantitative assay has a measurable range of at least eight orders of magnitude, generating adequate linearity up to 8 log IU/mL ($R^2 = 0.9976$). The LOD of Daan HCV RNA quantitative assay was 15 log IU/mL which was comparable with COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test whose LOD was also 15 log IU/mL. Meanwhile, the HCV RNA quantitative assay with a 15 IU/mL limit of detection has been advocated by the Centers for Disease Control of United States and European Society of Liver Diseases as the confirmation test for HCV infection. What's more, 700 μL serum or plasma was needed for COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test while only 200 μL serum or plasma was needed for the Daan HCV RNA quantitative assay, suggesting the Daan HCV RNA quantitative assay needed less specimen volume to get a comparable performance. What's more, the Daan HCV RNA quantitative assay was of high specificity for it did not display any interference with commonly encountered conditions and other viral illnesses. From all above, the DAAN quantitative showed good precision and accuracy and exhibited a wide range of quantification, a comparable LOD and high specificity, indicating its excellent analytical performance. Moreover, our study was the first to evaluate this recently developed and certified diagnostic kit for quantification of hepatitis C virus RNA.

### TABLE 1

Precision of the DAAN HCV RNA quantitative assay

| Expected, IU/mL | Log$_{10}$ IU/mL | Daily Mean ± SD (log IU/mL) | Grand Mean ± SD (log IU/mL) | $S_{\text{within}}$ | B | $S_{\text{total}}$ |
|-----------------|------------------|-----------------------------|-----------------------------|---------------------|---|------------------|
| $1.30 \times 10^6$ | 6.11             | 6.36 ± 0.07                 | 6.28 ± 0.15                 | 0.13                | 0.01 | 0.15 |
|                 |                  | 6.21 ± 0.14                 |                             |                     |     |      |
|                 |                  | 6.42 ± 0.04                 |                             |                     |     |      |
|                 |                  | 6.21 ± 0.15                 |                             |                     |     |      |
|                 |                  | 6.21 ± 0.19                 |                             |                     |     |      |
| $1.66 \times 10^4$ | 4.22             | 4.02 ± 0.07                 | 4.09 ± 0.08                 | 0.07                | 0.004 | 0.09 |
|                 |                  | 4.09 ± 0.06                 |                             |                     |     |      |
|                 |                  | 4.03 ± 0.07                 |                             |                     |     |      |
|                 |                  | 4.15 ± 0.05                 |                             |                     |     |      |
|                 |                  | 4.16 ± 0.04                 |                             |                     |     |      |
| $2.10 \times 10^2$ | 2.32             | 2.53 ± 0.09                 | 2.57 ± 0.11                 | 0.11                | 0.001 | 0.10 |
|                 |                  | 2.57 ± 0.09                 |                             |                     |     |      |
|                 |                  | 2.54 ± 0.10                 |                             |                     |     |      |
|                 |                  | 2.59 ± 0.12                 |                             |                     |     |      |
|                 |                  | 2.63 ± 0.12                 |                             |                     |     |      |

Abbreviations: B, variance term; SD, standard deviation; $S_{\text{total}}$, total precision; $S_{\text{within}}$, within-run precision.

### TABLE 2

Accuracy of the DAAN HCV RNA quantitative assay

| Expected, IU/mL | Log IU/mL | Mean | SD | CV (%) |
|-----------------|-----------|------|----|--------|
| $10^5$          | 5         | 4.90 | 0.06 | 1.26   |
| $10^4$          | 4         | 3.84 | 0.04 | 1.08   |
| $10^3$          | 3         | 3.07 | 0.10 | 3.10   |
| $10^2$          | 2         | 2.16 | 0.09 | 3.95   |
| 50              | 1.7       | 1.62 | 0.18 | 11     |

Abbreviations: CV, coefficient of variation; SD, standard deviation.
Good agreement was observed between the Daan HCV RNA quantitative assay and COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test on clinical specimens, indicating good clinical performance of the DAAN HCV RNA quantitative assay. Positive and negative agreement between them was 99%, suggesting a re-baseline of patients is not needed when switching to the Daan HCV RNA quantitative assay for HCV testing. The Daan HCV RNA quantitative assay is a good candidate for diagnosing HCV and monitoring HCV viral load of patients during HCV therapy. From the comparison results, we could find that the specimen sets were enriched to 4-7 log IU/mL viral load ones. The samples maybe tended to be uniform because of the homogeneous patient population. During the HCV RNA extraction, it could be carried out on automatic nucleic acid extractor platform Smart 32, which could avoid labor-intensive manual extraction and reduce artificial error. Moreover, the price for per Daan HCV RNA quantitative assay
was almost a quarter of that for the Roche Cobas test, making it affordable in many central laboratories in developing countries. With the advantage of low price and satisfactory analytical performance and clinical performance, the Daan HCV RNA quantitative assay would be a good alternative choice for the diagnosis and monitoring HCV RNA. However, the performance evaluation of the assay was carried out in only one central laboratory in China. Further studies on the performance evaluation of the Daan HCV RNA quantitative assay should be conducted at regional and peripheral level laboratories.

In summary, evaluation of the performances of the Daan HCV RNA quantitative assay confirmed the excellent characteristics of the assay regarding the precision, accuracy, linearity, anti-interference ability, and good agreement with the Roche assay, making

### TABLE 3 HCV RNA quantitative results with different interferents

| Expected (IU/mL) | Log IU/mL | Expected range (Mean ± 2SD log IU/mL) | Interferent | Interferent concentration | Mean ± SD (log IU/mL) |
|------------------|-----------|--------------------------------------|-------------|--------------------------|---------------------|
| 2.21 × 10³ | 3.34 | 2.83-3.87/ | / | / | 3.24 ± 0.09 |
| 2.77 × 10⁵ | 5.44 | 4.94-5.95/ | / | / | 5.59 ± 0.02 |
| Bilirubin | 30 mg/dL | 3.06 ± 0.10 |
| Triglyceride | 3.2 g/dL | 3.16 ± 0.05 |
| Hemoglobin | 30 g/dL | 3.02 ± 0.02 |
| Albumin | 6 g/dL | 3.21 ± 0.08 |
| Total immunoglobulin G | 18 g/L | 3.19 ± 0.15 |
| Bilirubin | 30 mg/dL | 5.56 ± 0.06 |
| Triglyceride | 3.2 g/dL | 5.62 ± 0.02 |
| Hemoglobin | 30 g/dL | 5.49 ± 0.01 |
| Albumin | 6 g/dL | 5.53 ± 0.11 |
| Total immunoglobulin G | 18 g/L | 5.59 ± 0.01 |

Abbreviation: SD, standard deviation.

### FIGURE 2 Deming linear regression analysis of HCV RNA levels and Bland-Altman plot of data for all the clinical specimens showing the bias between the Roche Cobas test and Daan HCV assay. A, Deming linear regression analysis of HCV RNA levels for 81 serum specimens. The fitted regressions are represented with solid line. B, Agreement between the HCV RNA quantification by plotting the differences between the Roche Cobas test and Daan HCV assay averages of the two techniques using the Bland-Altman analysis. Continuous line with the 95% limits of the agreement represents the mean bias between the two tests, and dashed lines represent the 95% confidence interval.
it a good alternative choice for the diagnosis and monitoring of HCV infection in developing countries.

ORCID
Yuting He https://orcid.org/0000-0001-7133-9501
Peisong Chen https://orcid.org/0000-0003-0640-3663

REFERENCES
1. Xie Q, Xuan JW, Tang H, et al. Hepatitis C virus cure with direct acting antivirals: clinical, economic, societal and patient value for China. World J Hepatol. 2019;11(5):421-441.
2. Hill AM, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. J Virus Erad. 2017;3(3):117-123.
3. Zhou B, Cai GFF, Lv HKK, et al. Factors correlating to the development of hepatitis C virus infection among drug users-findings from a systematic review and meta-analysis. Int J Environ Res Public Health. 2019;16(13):2345.
4. Wilkins T, Akhtar M, Gititu E, Jalluri C, Ramirez J. Diagnosis and management of hepatitis C. Am Fam Physician. 2015;91(12):835-842.
5. Vermehren J, Bourliere M, Pol S, et al. Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. J Clin Virol. 2017;89:51-56.
6. Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol. 2008;46(12):3880-3891.
7. Zhao N, Liu J, Sun D. Detection of HCV genotypes 1b and 2a by a reverse transcription loop-mediated isothermal amplification assay. J Med Virol. 2017;89(6):1048-1054.
8. Marins EG, Bodinaidu K, Lin M, Deforest A. Evaluation of the COBAS(R)(R) AmpliPrep/COBAS(R)(R) TaqMan(R)(R) HCV Test v2.0 for HCV viral load monitoring using dried blood spot specimens. J Virol Methods. 2017;247:77-80.
9. Mazzuti L, Lozzi MA, Riva E, et al. Evaluation of performances of VERSANT HCV RNA 1.0 assay (kPCR) and Roche COBAS AmpliPrep/COBAS TaqMan HCV test v2.0 at low level viremia. New Microbiol. 2016;39(3):224-227.
10. CLSI. User verification of performance for precision and true-ness; approved guideline-second edition. In: Carey RN, Anderson FP, George H, eds. CLSI Documents EP 15-A2. Wayne, PA: CLSI; 2008:6-14.
11. CLSI. Evaluation of the linearity of quantitative analytical methods; approved guideline. In: Daniel W, Kroll M, Astles JR, eds. CLSI Documents EP 6-A. Wayne, PA: CLSI; 2003:4-18.
12. CLSI. Protocols for determination of limits of detection and limits of quantitation. Approved guidelines. In: Daniel W, Linnet K, Kondratovich M, eds. CLSI Documents EP 17-A. Wayne, PA: CLSI; 2004:5-25.
13. Nouhin J, Bollore K, Castera-Guy J, et al. Analytical and field evaluation of the biocentric generic HCV assay on open polyvalent PCR platforms in France and Cambodia. J Clin Virol. 2018;108:53-58.
14. CLSI. Interference testing in clinical chemistry; approved guideline-second edition. In: Robert J, Mary F, Donald M, eds. CLSI Documents EP 12-A. Wayne, PA: CLSI; 2005:5-36.
15. CLSI. User protocol for evaluation of qualitative test performance; approved guideline. In: Larry W, Patricia E, Martin R, eds. CLSI documents EP 12-A. Wayne, PA: CLSI; 2002:2-16.
16. Cunningham EB, Hajarizadeh B, Amin J, et al. Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. Clin Infect Dis. 2019:ciz1089. https://doi.org/10.1093/cid/ciz1089
17. Keast SL, Holderread B, Cothran T, Skrepnek GH. Hepatitis C direct-acting antiviral treatment selection, treatment failure, and use of drug-drug interactions in a state medicaid program. J Manag Care Spec Pharm. 2019;25(11):1261-1267.
18. Deeks ED. COBAS (R) AmpliPrep/COBAS (R) Taqman (R) HCV Quantitative Test, version 2.0: an in vitro test for hepatitis C virus RNA quantification. Mol Diagn Ther. 2015;19(1):1-7.
19. European Association for the Study of the Liver. Electronic address eee. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153-194.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: He Y, Wang Y, Chen X, et al. Performance evaluation of the DAAN HCV assay for quantification of hepatitis C virus RNA and its comparison with COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0. J Clin Lab Anal. 2020;34:e23280. https://doi.org/10.1002/jcla.23280